Fostrox + Lenvima shows further improved response rates and time to progression in advanced liver cancer (HCC) at ASCO GI Symposium

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

Related Keywords

Stockholm ,Sweden ,United States ,Spain ,Barcelona ,Comunidad Autonoma De Cataluna ,American ,Jens Lindberg ,Magnus Christensen ,Maria Reig ,Pia Baumann , ,Overall Response Rate ,Nasdaq Stockholm ,American Society ,Clinical Oncology ,Gastrointestinal Cancers ,San Francisco ,Barcelona Clinic Liver Cancer ,Liver Oncology Unit ,Hospital Clinic ,Friday January ,Tuesday January ,Small Cap ,European Journal ,Medivir ,